Small molecule drug may prevent chemotherapy resistance
Scientists have discovered a small molecule drug that may stop cancer cells from becoming resistant to chemotherapy. Drug resistance is a major cause of cancer relapse and is responsible for as much as 90% of deaths related to the disease.
The new compound, which was tested in an animal model of melanoma, could make current chemotherapies more powerful. It works by thwarting cancer’s ability to survive, evolve, and adapt to the DNA damage created by traditional chemotherapy drugs like cisplatin.
“Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug, and the next, and the next,” said senior study co-author Pei Zhou, Ph.D., a professor of biochemistry at Duke University School of Medicine.
“It reminds me of Boggarts, those shapeshifting creatures from Harry Potter that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good.”
The study was published June 6 in Cell.
In their simplest form, cancer cells are normal cells that are growing out of control. Each time these cells divide, the DNA within them must replicate to generate new copies to go inside each new cell. The first chemotherapy drugs were based on the rationale that rapidly growing cancer cells would be more sensitive to damage to their DNA. Drugs like cisplatin are designed to damage DNA, causing the sensitive replication machinery normally tasked with copying each strand to stall. If DNA replication is stalled for too long, cell division halts, and cells die.
The strategy is brutal and effective, even curative in some cases. But long-term, it often fails, as cancer cells figure out a way to proliferate even in the presence of DNA damage.
“The cancer cells often swap out the high fidelity replication machinery, which usually does the copying, with a sloppy replacement that covers up the lesions and moves on,” said Zhou. “As a result, the cells survive, but with mutations in their DNA.”
Because this process, known as translesion synthesis, is a major cause of cancer drug resistance, it has become a major area of study in cancer research. Scientists have identified a key protein involved, named Rev1, and have even disrupted it through genetic means — works done in the laboratories of Graham C. Walker and Michael T. Hemann at MIT, both senior co-authors of this study. However, attempts to do the same with small molecules had never succeeded, presumably because the protein lacked an obvious binding pocket that a potential drug could exploit.
In this study, Zhou and his collaborators at Duke, MIT, and the University of Rhode Island decided to try their luck at finding a small molecule to block or inhibit Rev1. They screened 10,000 small molecule compounds, and were surprised to find that one — a molecule called JH-RE-06 — appeared to do the trick.
The researchers used a technique called x-ray crystallography to visualize the unexpected interactions between Rev1 and JH-RE-06. They found that when Rev1 interacts with JH-RE-06, it pairs up or dimerizes with another copy of itself, creating a binding pocket where there wasn’t one before. When Rev1 is locked up in this dimer, it can no longer help cancer cells survive and attain their shape-shifting powers.
The researchers then tested the new molecule in human cancer cell lines and showed that it enhanced the ability of several forms of chemotherapy to kill cells, while also suppressing their ability to mutate in the presence of DNA-damaging drugs. Finally, they tested it in a mouse model of human melanoma. They found that not only did the tumors stop growing in mice treated with a combination of cisplatin and JH-RE-06, but also that those mice survived longer.
Senior study co-author Jiyong Hong, PhD, a professor of chemistry at Duke, said that they are currently creating versions of JH-RE-06 that have enhanced pharmacologic properties that could make it an even more attractive drug. “This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic.”
The Latest on: Cancer drug resistance
via Google News
The Latest on: Cancer drug resistance
- CDC Warning: Antibiotic-Resistant Fungal Infections Are Still a Big Problemon November 30, 2019 at 1:03 am
During this time, the risk for serious fungal infections rose as more people suffered weakened immune systems stemming from increased bone marrow and organ transplantation, new drugs to treat cancer ...
- News digest – Heart health risks, immunotherapy trials, prostate cancer urine test and living with canceron November 30, 2019 at 12:07 am
BBC News covers the results of a trial testing an immunotherapy drug for some men with prostate cancer that’s spread to other parts of the body and become resistant to treatment. The study involved ...
- National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indicationon November 29, 2019 at 4:44 am
Epigenetic abnormality is a common biological basis for drug resistance, tumor recurrence and metastasis in cancer patients. Chidamide is a selective HDAC inhibitor with unique epigenetic mechanisms ...
- Endosomal Sorting Complex Required for Transport (ESCRT): Investigation of the role in acquired drug resistance in colon canceron November 29, 2019 at 3:40 am
and one of the major problems is the build-up of resistance to cancer drugs during treatment (‘acquired resistance’) such that over time the drugs stop working. Whilst we have some understanding of ...
- A Small Number Of Men With Prostate Cancer Are ‘Super Responders’ To Immunotherapyon November 28, 2019 at 4:03 pm
The number of men who responded to the drug, pembrolizumab (also known as Keytruda ... The study involved 259 men with advanced prostate cancer who had become resistant to conventional therapies such ...
- Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cellson November 27, 2019 at 2:41 am
However, the underlying upstream regulatory mechanisms of Sema4C-induced EMT and Sema4C-mediated drug resistance are still unclear. The aim of this study was to explore the potential role of miR-31-3p ...
- The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cellson November 27, 2019 at 2:17 am
Lung cancer patients face a dismal prognosis mainly due to the low efficacy of current available treatments. Cisplatin is the first-line chemotherapy treatment for those patients, however, resistance ...
- Gran Fondo rider discovers skin cancer drug planon November 26, 2019 at 1:32 pm
According to the Skin Cancer Foundation, more than 192,000 people will be diagnosed with melanoma this year. Misek discovered a combination of drugs that could help those with drug-resistant melanoma.
- Is Myovant's New Prostate Cancer Drug a Game Changer?on November 26, 2019 at 10:46 am
While many drugs exist that cater to prostate cancer patients who have become resistant to initial androgen-lowering treatments, there's a strong market for drugs that can target prostate cancer while ...
- PhoenixMD Adds Seed Funding to Test Experimental Breast Cancer Drugon November 26, 2019 at 5:29 am
While designed specifically to target TNBC, the company is developing PMD-026 as a platform technology to treat various resistant forms of cancer. Dunn says the company will continue expanding ...
via Bing News